Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

J. J. Knox; C. H. Barrios; T. M. Kim; T. Cosgriff; V. Srimuninnimit; K. Pittman; R. Sabbatini; S. Y. Rha; T. W. Flaig; R. D. Page; J. T. Beck; F. Cheung; S. Yadav; P. Patel; L. Geoffrois; J. Niolat; N. Berkowitz; M. Marker; D. Chen; R. J. Motzer

doi:10.1093/ANNONC/MDX807

Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

J. J. Knox
, C. H. Barrios
, T. M. Kim
, T. Cosgriff
, V. Srimuninnimit
, K. Pittman
, R. Sabbatini
, S. Y. Rha
, T. W. Flaig
, R. D. Page
, J. T. Beck
, F. Cheung
, S. Yadav
, P. Patel
, L. Geoffrois
, J. Niolat
, N. Berkowitz
, M. Marker
, D. Chen
, R. J. Motzer

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	29
Issue number	11
DOIs	https://doi.org/10.1093/ANNONC/MDX807
State	Published - Nov 1 2018

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1093/ANNONC/MDX807License: Unspecified

Cite this

Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., & Motzer, R. J. (2018). Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). Annals of Oncology, 29(11). https://doi.org/10.1093/ANNONC/MDX807

Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). / Knox, J. J.; Barrios, C. H.; Kim, T. M. et al.
In: Annals of Oncology, Vol. 29, No. 11, 01.11.2018.

Research output: Contribution to journal › Article › peer-review

Knox, JJ, Barrios, CH, Kim, TM, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, SY, Flaig, TW, Page, RD, Beck, JT, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D & Motzer, RJ 2018, 'Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)', Annals of Oncology, vol. 29, no. 11. https://doi.org/10.1093/ANNONC/MDX807

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K et al. Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). Annals of Oncology. 2018 Nov 1;29(11). doi: 10.1093/ANNONC/MDX807

@article{bb006adef2bb4f9ba5ef74079b3c0bc9,

title = "Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)",

author = "Knox, \{J. J.\} and Barrios, \{C. H.\} and Kim, \{T. M.\} and T. Cosgriff and V. Srimuninnimit and K. Pittman and R. Sabbatini and Rha, \{S. Y.\} and Flaig, \{T. W.\} and Page, \{R. D.\} and Beck, \{J. T.\} and F. Cheung and S. Yadav and P. Patel and L. Geoffrois and J. Niolat and N. Berkowitz and M. Marker and D. Chen and Motzer, \{R. J.\}",

note = "In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected. Publisher Copyright:{\textcopyright} The Author(s) 2018. All Science Journal Classification (ASJC) codes Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Flaig, T.",

year = "2018",

month = nov,

day = "1",

doi = "10.1093/ANNONC/MDX807",

language = "American English",

volume = "29",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

AU - Knox, J. J.

AU - Barrios, C. H.

AU - Kim, T. M.

AU - Cosgriff, T.

AU - Srimuninnimit, V.

AU - Pittman, K.

AU - Sabbatini, R.

AU - Rha, S. Y.

AU - Flaig, T. W.

AU - Page, R. D.

AU - Beck, J. T.

AU - Cheung, F.

AU - Yadav, S.

AU - Patel, P.

AU - Geoffrois, L.

AU - Niolat, J.

AU - Berkowitz, N.

AU - Marker, M.

AU - Chen, D.

AU - Motzer, R. J.

N1 - In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected. Publisher Copyright:© The Author(s) 2018. All Science Journal Classification (ASJC) codes Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Flaig, T.

PY - 2018/11/1

Y1 - 2018/11/1

UR - https://yonsei.pure.elsevier.com/en/publications/erratum-final-overall-survival-analysis-for-the-phase-ii-record-3

U2 - 10.1093/ANNONC/MDX807

DO - 10.1093/ANNONC/MDX807

M3 - Article

SN - 1569-8041

VL - 29

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

Disciplines

Access to Document

Other files and links

Cite this